Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

ABSTRACT:

Background

Myelofibrosis is a Philadelphia chromosome–negative myeloproliferative neoplasm associated with cytopenias, splenomegaly, poor quality of life, and shortened survival. About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiology of the disease. INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.

Methods

We conducted a phase 1−2 trial of INCB018424 in patients with JAK2 V617F−positive or JAK2 V617F−negative primary myelofibrosis, post–essential thrombocythemia myelofibrosis, or post–polycythemia vera myelofibrosis.

Results

A total of 153 patients received INCB018424 for a median duration of more than 14.7 months. The initial dose-escalati

SUBMITTER: Verstovsek S 

PROVIDER: S-EPMC5187954 | biostudies-literature | 2010 Sep

REPOSITORIES: biostudies-literature